drugset / Trial / NCT06654700

Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

NCT06654700

Phase 3 Not yet recruiting 1200 enrolled MAXVAX Biotechnology Limited Liability Company
RandomizedParallel-groupTriple-blindPrevention

Summary

To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.

Timeline

Start
2024-12-09
Primary completion
2025-05-01
Completion
2025-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Zoster Vaccine (CHO Cell) Vaccine 50 ug Intramuscular
Subject Recombinant Zoster Vaccine (CHO Cell) Vaccine 0.5 ml Intramuscular

Indications